Opinion

Video

Evaluating Quality of Life and Adherence With mCRC Treatment Options

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Marwan Fakih, MD

Medical experts discuss the impact of third-line therapies (regorafenib, fruquintinib, FTD/TPI plus bevacizumab) on patient quality of life and share insights on patient adherence to these treatments.

Video content above is prompted by the following:

  1. What has been your experience with the impact of these third-line therapy options (regorafenib, fruquintinib, FTD/TPI plus bevacizumab) on a patient’s quality of life?
  2. What insights can you share related to patient adherence with third-line therapies in metastatic colorectal cancer?
Related Videos
Marc Humbert, MD, PhD
John Ostrominski, MD
John Buse, MD, PhD
Christian T. Ruff, MD, MPH
Dr Geoffrey Rutledge
Jason Bellet of Eko Health
Dr Geoffrey Rutledge
3 experts are featured in this series.
Related Content
Krazati packaging | Image credit: Mirati Therapeutics
March 28th 2025

Updated KRYSTAL-7 Data Show PFS Beyond 27 Months for Adagrasib Plus Pembro in First-line Treatment of KRAS-mutated NSCLC

Mary Caffrey
Phase 2 results reported at the European Lung Cancer Conference show a favorable signal for overall survival for the first-line treatment of KRAS-mutated non–small cell lung cancer (NSCLC). A phase 3 trial is enrolling now.
managed care cast logo
December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick
On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.
Astigmatism | Image credit: Zarina Lukash - stock.adobe.com
March 26th 2025

Prevalence, Severity of Astigmatism Increased in Children After Pandemic

Julia Bonavitacola
Both refractive and corneal astigmatism saw an increase in prevalence in children after the COVID-19 pandemic, with corneal changes potentially playing a part.
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.
Pulmonary hypertension | Image Credit: © Uladzislau-stock.adobe.com
March 26th 2025

PAH Therapies Improve Outcomes in PH-ILD

Maggie L. Shaw
Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.
FDA approval graphic | Image Credit: wladimir1804 - stock.adobe.com
March 25th 2025

FDA Approves First New Class of Oral Antibiotics for Uncomplicated UTIs in Nearly 30 Years

Brooke McCormick
The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract infections (UTIs) in nearly 30 years.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo